ArticleCureus2026
Biopsy-Proven Glomerular Diseases in Saudi Arabia: The Clinicopathological Spectrum and Predictors of Renal Outcomes in a Single-Center Cohort and Four Decades of National Data.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Glomerular diseases are a significant contributor to chronic kidney disease (CKD) in Saudi Arabia. Local data linking biopsy findings to renal outcomes are scarce, and the available series are mostly descriptive. Objectives The objective of this study is to characterize the clinicopathological spectrum of biopsy-proven glomerular disease at a single Saudi tertiary center, identify histological and clinical predictors of renal function decline at one year, and secondarily compare these findings descriptively with previously published Saudi biopsy series. Methods We retrospectively reviewed native kidney biopsies performed over a 24-year period. The primary outcome was a composite renal endpoint at one year (≥ 40% decline in eGFR or eGFR < 15 mL/min/1.73 m²), with sensitivity analyses using a 30% decline threshold. Predictors were assessed by multivariable logistic regression in a complete-case cohort of 289 patients. Results Of 700 biopsies screened, 333 met the inclusion criteria. The most common diagnoses were lupus nephritis (72; 21.6%), followed by focal segmental glomerulosclerosis (FSGS) (60; 18%), diabetic nephropathy (46; 13.8%), and IgA nephropathy (35; 10.5%). FSGS was the most common primary glomerular lesion, and lupus nephritis was the leading secondary diagnosis. Overall, 124 of 314 patients with follow-up (39%) reached the composite outcome at one year. Moderate to severe interstitial fibrosis and tubular atrophy (IFTA) (aOR 2.13, 95% CI 1.14-3.98; p = 0.018) and moderate to severe arteriosclerosis (aOR 2.38, 95% CI 1.09-5.26; p = 0.034) independently predicted the outcome, as did higher 24-hour urinary protein (aOR 1.08 per g/day, 95% CI 1.01-1.15; p = 0.026) and lower baseline eGFR (aOR 0.98 per mL/min/1.73 m², 95% CI 0.97-0.99; p < 0.001). Conclusion In this 24-year biopsy cohort, chronic histopathological damage was an independent predictor of renal function decline at one year, alongside proteinuria and baseline eGFR. These findings show that chronicity on biopsy carries prognostic weight and support the need for dedicated national glomerulonephritis (GN) registries combining histopathological findings with longitudinal follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.